Cessatech A/S (8GN.F)
- Previous Close
0.7440 - Open
0.7620 - Bid 0.7220 x --
- Ask 0.8560 x --
- Day's Range
0.7100 - 0.7620 - 52 Week Range
0.2020 - 0.9480 - Volume
33 - Avg. Volume
2 - Market Cap (intraday)
14.224M - Beta (5Y Monthly) 0.09
- PE Ratio (TTM)
-- - EPS (TTM)
-0.2400 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Cessatech A/S engages in identifying and developing drugs for the treatment of medical unmet need in children in Denmark. The company's lead product is CT001, an analgesic nasal spray for the treatment of acute and planned painful procedures in children. It also develops CT002, a nasal spray for magnetic resonance imaging scanning; and CT003, a local anesthetic gel. The company has a collaboration and license agreement with Ventis Pharma Corporation to develop and formulate pain management therapies. Cessatech A/S was incorporated in 2020 and is based in Copenhagen, Denmark.
www.cessatech.comRecent News: 8GN.F
Performance Overview: 8GN.F
Trailing total returns as of 5/28/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 8GN.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 8GN.F
Valuation Measures
Market Cap
14.34M
Enterprise Value
12.32M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
5.12
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-76.69%
Return on Equity (ttm)
-241.86%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-26.53M
Diluted EPS (ttm)
-0.2400
Balance Sheet and Cash Flow
Total Cash (mrq)
3.37M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-12.65M